Skip to Main Content

Paper Details

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
EBioMedicine
31
2020
ALK, ALK+, ALK+ NSCLC, ALK-positive lung cancer, ALK-rearranged lung cancer, BRAF, CNVs, Cancer, Circulating, Circulating tumour, EGFR, EML4, ERBB2, KIT, MET, NSCLC, SNV, TP53, TP53 mutations, cell, cell-free DNA, cfDNA, ctDNA, mutant ctDNA allele, patient, patients, plasma DNA samples, single nucleotide variant, tumour
Author NameAffiliation
Anna-Lena VolckmarInstitute of Pathology, Heidelberg University
Tomasz ZemojtelBerlin Institute of Health (BIH) Genomics Core Facility, University Medical Center
Daniel KazdalGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg, Germany Institute of Pathology, Heidelberg University
Volker EndrisInstitute of Pathology, Heidelberg University
Matthias SchlesnerGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg, German Cancer Research Center (DKFZ)
Matthias SchlesnerGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg, German Cancer Research Center (DKFZ)
Albrecht StenzingerInstitute of Pathology, Heidelberg University
Holger S??ltmannGerman Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), Germany German Center for Lung Research (DZL), Translational Lung Research Center Heidelberg
  • 1 - 8

Datasets

Release 1.2